» Articles » PMID: 19682544

Motor Cortex Stimulation for ALS: a Double Blind Placebo-controlled Study

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2009 Aug 18
PMID 19682544
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Preliminary data suggest that repetitive transcranial magnetic stimulation (rTMS) of the brain may produce a modest slowing of disease progression in amyotrophic lateral sclerosis (ALS). The present study was designed to test the hypothesis that rTMS given as continuous theta burst stimulation (cTBS), repeated monthly for one year, would affect ALS progression. We performed a double blind, placebo-controlled trial. Twenty patients with ALS were randomly allocated to blinded real or placebo stimulation. cTBS of the motor cortex was performed for five consecutive days every month for one year. Primary outcome was the rate of decline as evaluated with the revised ALS functional rating scale (ALSFRS-R). Treatment was well tolerated. There was no significant difference in the ALSFRS-R score deterioration between patients treated with real or placebo stimulation. ALSFRS-R mean scores declined from 32.0 (SD 7.1) at study entry to 23.1 (SD 6.3) at 12 months in patients receiving real cTBS and from 31.3 (SD 6.9) to 21.2 (SD 6.0) in those receiving placebo stimulation. Although cTBS proved a safe procedure, on the basis of the present findings a larger randomized confirmatory trial seems unjustified in ALS patients, at least in advanced stage of the disease.

Citing Articles

Exercises and Brain Stimulation to Preserve Function in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.

Banos M, Preuilh A, Pradat P, Lackmy-Vallee A, Marchand-Pauvert V Neurol Clin Pract. 2024; 15(1):e200408.

PMID: 39678223 PMC: 11637470. DOI: 10.1212/CPJ.0000000000200408.


Transcranial static magnetic stimulation for amyotrophic lateral sclerosis: a bicentric, randomised, double-blind placebo-controlled phase 2 trial.

Di Lazzaro V, Ranieri F, Doretti A, Boscarino M, Maderna L, Colombo E Lancet Reg Health Eur. 2024; 45:101019.

PMID: 39185360 PMC: 11341967. DOI: 10.1016/j.lanepe.2024.101019.


Efficacy of non-pharmacological interventions for individuals with amyotrophic lateral sclerosis: systematic review and network meta-analysis of randomized control trials.

Li Z, Kang H Sci Rep. 2024; 14(1):11365.

PMID: 38762656 PMC: 11102473. DOI: 10.1038/s41598-024-62213-w.


Current perspectives on neuromodulation in ALS patients: A systematic review and meta-analysis.

Jimenez-Garcia A, Bonnel G, Alvarez-Mota A, Arias N PLoS One. 2024; 19(3):e0300671.

PMID: 38551974 PMC: 10980254. DOI: 10.1371/journal.pone.0300671.


Neuronal Hyperexcitability and Free Radical Toxicity in Amyotrophic Lateral Sclerosis: Established and Future Targets.

Shibuya K, Otani R, Suzuki Y, Kuwabara S, Kiernan M Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455429 PMC: 9025031. DOI: 10.3390/ph15040433.